Bright Minds Biosciences is an early-stage biotech company that aims to create new (novel) psychedelics to treat mental health disorders. One aim is to prevent bad trips.
Bright Minds Biosciences
“We harness our team’s decades of experience in the biology of the serotonergic system to understand the effect specific receptors have on our body. From there, we create new and modify existing molecules in order to reduce unwanted side effects and accentuate positive therapeutic properties.”
Bright Minds are listed on the CNX under the ticker DRUG.
In March 2021 Bright Minds announced it raised a total of $20.7 million US following IPO.
Key Staff
- Alan Kozikowski – Lead Scientist
News
- Conversations: Ian McDonald and Dr. Gideon Shapiro, Bright Minds Biosicences (Report on Psychedelics, May 2020)
- This Drug Designer Is Creating a New Psychedelic to Treat Anxiety and Depression (Vice, May 2020)
Activities
B2B
B2C
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates